Celldex Therapeutics
CLDX
197 hedge funds and large institutions have $2.91B invested in Celldex Therapeutics in 2024 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 81 increasing their positions, 43 reducing their positions, and 13 closing their positions.
262% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 13
88% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 43
20% more capital invested
Capital invested by funds: $2.42B → $2.91B (+$490M)
20% more funds holding
Funds holding: 164 → 197 (+33)
3.92% less ownership
Funds ownership: 111.52% → 107.59% (-3.9%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
59% less call options, than puts
Call options by funds: $9.84M | Put options by funds: $24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$110M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$109M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$48.1M |
| 4 |
BlackRock
New York
|
+$34.3M |
| 5 |
Jennison Associates
New York
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$137M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$60.5M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$30M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$28.1M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21M |
CLDX Hedge Fund Activity: Q1 2024 in Review
197 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2024, worth a combined $2.91B — up 20% from $2.42B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new CLDX positions and 13 closed out — a net gain of 34 holders — while 81 added to existing stakes and 43 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $110M. The largest seller was RTW Investments, exiting entirely with an estimated $137M sold.
- 197 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2024, up from 164 in Q4 2023.
- Funds reported $2.91B of Celldex Therapeutics stock for Q1 2024, up 20% quarter-over-quarter.
- 47 funds opened new Celldex Therapeutics positions in Q1 2024 and 13 closed out, a net change of +34 holders.
- The largest Celldex Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $110M added.
- The largest Celldex Therapeutics seller in Q1 2024 was RTW Investments, an estimated $137M sold.
Based on aggregated 13F filings for Q1 2024.